Relation of visfatin to cardiovascular risk factors and adipocytokines in patients with impaired fasting glucose

Nutrition

Volumn 29, Issue 11-12, 2013, Pages 1300-1303

  de Luis, Daniel Antonio ^a   Sagrado, Manuel González ^a   Conde, Rosa ^a   Aller, Rocio ^a   Izaola, Olatz ^a  

^a UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

Adipocytokines; Cardiovascular risk factors; Impaired fasting glucose; Visfatin

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; INSULIN; INTERLEUKIN 6; LEPTIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD PRESSURE MEASUREMENT; BODY MASS; BODY WEIGHT; CALORIMETRY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIETARY INTAKE; DISEASE ASSOCIATION; FAT FREE MASS; FAT MASS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; IMPEDANCE; INSULIN BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOCYTOKINES; CARDIOVASCULAR RISK FACTORS; IMPAIRED FASTING GLUCOSE; VISFATIN;

ADIPOKINES; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; BODY WEIGHT; C-REACTIVE PROTEIN; CALORIMETRY, INDIRECT; CHOLESTEROL; ENERGY INTAKE; FEMALE; HUMANS; INSULIN; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PREDIABETIC STATE; PROSPECTIVE STUDIES; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84884977235     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2008.11.005     Document Type: Article

References (21)

1. Frayn K.N. Subcutaneous and visceral adipose tissue their relation to metabolic syndrome. Endocr Rev 2000, 21:697-738.
2. Fukuhara A., Matsuda M., Nishizawa M., Sagawa K., Tanaka M., Kishimoto K., et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005, 307:426-430.
3. Ognjanovic S. Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. JMol Endocrinol 2001, 26:107-117.
4. FU Cahn T.F., Chen L., Kee C.H., Chou F.H., Wu L.C., Jong S.B., et al. Decreased plasma visfatin concentration in women with gestational diabetes mellitus. J Soc Gynecol Investig 2006, 13:364-367.
5. Krzyzanowska K., Krugluger W., Mittermayer F., Rahma R., Haider D., Shnawa N. Increased visfatin concentrations in women with gestational diabetes mellitus. Clin Sci 2006, 1:605-609.
6. Hammastedt A., Pihlajamaki J., Sopasakis V., Gogg S., Jansso P.A., et al. Visfatin is an adipokine, but it is not regulated by thiazolidinediones. J Clin Endocrin Metab 2006, 91:1181-1184.
7. Tsiotra P.C., Tsigos C., Yfanti E., Anastasiou E., Vilentiou M., Psarra K., et al. Visfatin, TNF alpha and IL-6 mRNA expression is increases in mononuclear cells from type 2 diabetic women. Horm Metab Res 2007, 39:758-763.
8. Mathews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-414.
9. Pichard C., Slosman D., Hirschel B., Kyle U. Bioimpedance analysis in patients: an improved method for nutritional follow up. Clin Res 1993, 41:53a.
10. Feurer I.D., Mullen J.L. Bedside measurement of resting energy expenditure and respiratory quotient via indirect calorimetry. Nutr Clin Pract 1986, 1:43-49.
11. Mataix J., Mañas M. Tablas de composición de alimentos españoles 2003, University of Granada, Granada, Spain.
12. de Luis D.A., Gonzalez Sagrado M., Conde R., Aller R., Izaola O., Romero E. Effect of a hypocaloric diet on serum visfatin in obese non-diabetic patients. Nutrition 2008, 24:517-521.
13. Senthi J.K., Vidal Puig A. Visfatin: the missing link between intra-abdominal obesity and diabetes?. Trends Mol Med 2005, 11:344-350.
14. Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, Genc H, Smith U. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerant. Diabetes Res Clin Pract 2006;76:24-9.
15. Li L., Yang G., Li Q., Tang Y., Yahg M., Yang H., Li K. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes 2006, 114:544-548.
16. Hector J., Schwarzloh B., Goehring J., Strate T.G., Hess U.F., Deuretzbacher G., et al. TNF-alpha alters visfatin and adiponectin levels in human fat. Horm Metab Res 2007, 39:250-255.
17. Marcinkowska M., Lewandoski K.C., Lewinski A., Bienkiewicz M., Basinska M., Salata I., et al. Visfatin levels do not change after the oral glucose tolerance test and after a DXM induced increase in insulin resistance in humans. Endokrynol Pol 2007, 58:188-194.
18. Choi K.C., Ryu O.H., Lee K.W., Kim H.Y., Seo J.A., Kim S.G., et al. Effect of PPAR alpha and gamma on the expression of visfatin, adiponectin and TNF alpha invisceral fat of OLETF rats. Biochem Biophys Res Commun 2005, 336:747-753.
19. Jin H., Jiang B., Tang J., Lu W., Wang W., Zhou L., et al. Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol. Diabetes Res Clin Pract 2008, 79:412-418.
20. Sun G., Bishop J., Khalalli S., Vasdev S., Gill V., Pace D., et al. Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men. Am J Clin Nutr 2007, 85:399-404.
21. Lopez Bermejo A., Chico-Julia B., Fernandez-Balsells M., Recasens M., Esteve E. Serum visfatin increases with progressive beta cell deterioration. Diabetes 2006, 55:2871-2873.